èšåºæ®µéã®éºäŒåæ²»çäŒæ¥ã§ãã Voyager Therapeutics, Inc. ã¯ãé床ã®ç¥çµçŸæ£ã«èŠããæ£è
ã®æ²»çæ³ã®éçºã«æ³šåããŠããŸããå瀟ã®äž»åèšåºåè£ã¯ VY-AADC ã§ãããŒãã³ãœã³ç
ã®æ²»çãç®çãšãããªãŒãã³ã©ãã«ã®ç¬¬ 1b çžèšåºè©Šéšãè¡ãããŠããŸããå瀟ã®åèšåºããã°ã©ã ã«ã¯ãçèçž®æ§åŽçŽ¢ç¡¬åçã®æ²»çãç®çãšãã VY-SOD102ããã³ãã³ãã³ç
ã®æ²»çãç®çãšãã VY-HTT01ãããªãŒãã©ã€ãéå倱調çã®æ²»çãç®çãšãã VY-FXN01ãããã³ã¢ã«ããã€ããŒç
ãé²è¡æ§æ žäžæ§éº»çºãåé åŽé åèªç¥çãªã©ã®ã¿ãŠãªãããŒã®æ²»çãç®çãšãã Tau ããã°ã©ã ããããŸããå瀟ã¯ãããµãã¥ãŒã»ãã倧åŠãClearPoint Neuro, Inc. ãšæŠç¥çææºå¥çŽãçµãã§ããã»ããéºäŒåæ²»çããã°ã©ã ã®éçºããµããŒãããããã«ããµãŒã¢ãã£ãã·ã£ãŒãµã€ãšã³ãã£ãã£ãã¯ãå¯å£«ãã€ã«ã ãã€ãªã·ã³ã¹ãã€ãªãã¯ãããžãŒãºãšãææºããŠããŸãããŸããå瀟ã¯ã¢ããé䌎ãŠã€ã«ã¹ããŒã¹ã®éºäŒåæ²»ç補åã®ç ç©¶ãéçºãåååã«é¢ããŠãNeurocrine Biosciences, Inc. ãšææºããã³ã©ã€ã»ã³ã¹å¥çŽãçµãã§ããŸããVoyager Therapeutics, Inc. 㯠2013 幎ã«èšç«ãããããµãã¥ãŒã»ããå·ã±ã³ããªããžã«æ¬ç€Ÿã眮ããŠããŸãã